O2- CHARACTERIZATION OF STEATOTIC LIVER DISEASE AND THE ROLE OF GENETIC BACKGROUND IN LATIN AMERICA

Yes, FONDECYT #1241450 Although Latinos living in the United States are at higher risk of steatotic liver disease (SLD), information from Latin American countries is extremely scarce. We aimed to characterize SLD in Latin America and explore the role of the common genetic variants in this region. Cr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hepatology 2024-12, Vol.29, p.101597
Hauptverfasser: PIGA, LUIS ANTONIO DÍAZ, Aguilera, Carolina, Ayares, Gustavo, Idalsoaga, Francisco, Pizarro, Mauricio, Barreyro, Fernando Javier, Marciano, Sebastián, Morales, Jorge Martínez, Villela-Nogueira, Cristiane, Leite, Nathalie, Couto, Claudia Alves, Theodoro, Rafael, Monteiro, Mísia Joyner de Sousa Dias, Pessoa, Mario G., Alvares-da-Silva, Mario Reis, de la Tijera, Fátima Higuera, Lozano, Adelina, Montes, Pedro, Castro-Narro, Graciela, Sabate, Constanza D., Mendizabal, Manuel, Barrera, Francisco, Cabrera, Daniel, Noureddin, Mazen, Alkhouri, Naim, Dunn, Winston, Younossi, Zobair, Lazarus, Jeffrey V., Loomba, Rohit, de Oliveira, Claudia Pinto Marques Souza, Gadano, Adrian, Arrese, Marco, Arab, Juan Pablo
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Yes, FONDECYT #1241450 Although Latinos living in the United States are at higher risk of steatotic liver disease (SLD), information from Latin American countries is extremely scarce. We aimed to characterize SLD in Latin America and explore the role of the common genetic variants in this region. Cross-sectional multicenter study including individuals with SLD who undergo liver biopsy or transient elastography (TE) between 2003–2024. TE thresholds were established as follows: significant fibrosis (F2) ≥8.2 kPa, advanced fibrosis (F3) ≥9.7 kPa, and cirrhosis (F4) ≥13.6 kPa. Analyses included logistic binary regression. We included 2,159 patients (93.7% metabolic dysfunction-associated SLD and 6.3% alcohol-associated liver disease) from 13 centers in 5 countries (Argentina, Brazil, Chile, Mexico, and Peru). Mean age was 54.3±14.3 years old, 58.8% were female, and 60.2% had a liver biopsy. Around 18% had significant fibrosis, 18.7% advanced fibrosis, and 16.2% had cirrhosis. Additionally, 21.8% were homozygous carriers of the rs738409 risk polymorphism (PNPLA3 I148M variant), 42.5% were heterozygotes, and 35.7% were non-carriers. In an adjusted multivariable model, only age (odds ratio [OR]:1.03; 95%CI:1.01–1.04; p=0.030), body mass index (BMI) (OR:1.04; 95%CI:1.01–1.08, p=0.008), prediabetes/diabetes (OR:2.41; 95%CI:1.48–3.91, p
ISSN:1665-2681
DOI:10.1016/j.aohep.2024.101597